pirtobrutinib,rituximab,venetoclax
eli lilly,roche,abbvie
['leusm', 'bruin', 'lymsm', 'valent ,(-prevalent)', 'loxo', 'valent ,(-prevalent),(-equivalent),(-bivalent)']
join us at #eha2023 we re sharing results from the phase 1/2 bruin study, investigating a highly selective, non-covalent (reversible) btk inhibitor in relapsed/refractory waldenstr m macroglobulinemia. #leusm #lymsm view the results here: 
Dedicated to communicating the latest science & innovation from Loxo@Lilly. Tweets intended for US oncology HCPs. See our community guidelines: https://t.co/1q8vAe63mK